NO20061122L - 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer - Google Patents

2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer

Info

Publication number
NO20061122L
NO20061122L NO20061122A NO20061122A NO20061122L NO 20061122 L NO20061122 L NO 20061122L NO 20061122 A NO20061122 A NO 20061122A NO 20061122 A NO20061122 A NO 20061122A NO 20061122 L NO20061122 L NO 20061122L
Authority
NO
Norway
Prior art keywords
quinoxaline
ylsuflonylamino
cck2
benzamide compounds
modulators
Prior art date
Application number
NO20061122A
Other languages
English (en)
Norwegian (no)
Inventor
Michael D Hack
Brett Allison
Victor K Phuong
Michael H Rabinowitz
Mark D Rosen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20061122L publication Critical patent/NO20061122L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20061122A 2003-08-08 2006-03-08 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer NO20061122L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49407403P 2003-08-08 2003-08-08
PCT/US2004/025153 WO2005016896A1 (en) 2003-08-08 2004-08-04 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators

Publications (1)

Publication Number Publication Date
NO20061122L true NO20061122L (no) 2006-05-04

Family

ID=34193199

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061122A NO20061122L (no) 2003-08-08 2006-03-08 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer

Country Status (33)

Country Link
US (3) US7288651B2 (xx)
EP (2) EP1651621B1 (xx)
JP (2) JP4818110B2 (xx)
KR (1) KR20060060007A (xx)
CN (2) CN1863781A (xx)
AR (1) AR045930A1 (xx)
AT (2) ATE403650T1 (xx)
AU (2) AU2004265311A1 (xx)
BR (1) BRPI0413449A (xx)
CA (2) CA2534887A1 (xx)
CR (1) CR8229A (xx)
CY (1) CY1106486T1 (xx)
DE (2) DE602004004663T2 (xx)
DK (2) DK1651621T3 (xx)
EA (1) EA200600203A1 (xx)
EC (1) ECSP066355A (xx)
ES (2) ES2281834T3 (xx)
HR (1) HRP20080559T3 (xx)
IL (1) IL173591A0 (xx)
IS (1) IS8280A (xx)
LT (1) LT5410B (xx)
LV (1) LV13453B (xx)
MX (2) MXPA06001482A (xx)
NO (1) NO20061122L (xx)
NZ (1) NZ545030A (xx)
PL (2) PL1651621T3 (xx)
PT (2) PT1651622E (xx)
SG (1) SG131114A1 (xx)
SI (2) SI1651621T1 (xx)
TW (1) TW200521120A (xx)
UA (1) UA84025C2 (xx)
WO (2) WO2005016897A1 (xx)
ZA (1) ZA200601946B (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1651621T3 (da) * 2003-08-08 2008-11-10 Janssen Pharmaceutica Nv 2-(Quinoxalin-5-ylsulfonylamino)benzamidforbindelser som CCK2-modulatorer
WO2005085188A2 (en) * 2004-03-02 2005-09-15 Compass Pharmaceuticals Llc Compounds and methods for anti-tumor therapy
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
US7947833B2 (en) * 2004-08-04 2011-05-24 Janssen Pharmaceutica Nv Preparation of quinoxaline compounds
CA2581426A1 (en) 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Sulfonamide compounds
FR2904317A1 (fr) 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
US8592565B2 (en) * 2007-01-12 2013-11-26 The Board Of Trustees Of The Leland Stanford Junior University Preparation of azide-modified carbon surfaces for coupling to various species
EP2123644B1 (en) * 2007-03-07 2014-12-17 Takeda Pharmaceutical Company Limited Benzoxazepine derivatives and use thereof
WO2008124518A1 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor
EP2131245A3 (en) * 2008-06-02 2012-08-01 ASML Netherlands BV Lithographic apparatus and its focus determination method
WO2009154754A2 (en) * 2008-06-17 2009-12-23 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
US20100305093A1 (en) * 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using
JP5890312B2 (ja) 2009-10-09 2016-03-22 ザフゲン，インコーポレイテッド 肥満治療に用いられるスルホン化合物
WO2012004604A1 (en) 2010-07-09 2012-01-12 Convergence Pharmaceuticals Limited Tetrazole compounds as calcium channel blockers
KR20130043207A (ko) 2010-07-22 2013-04-29 자프겐 인크. 트리시클릭 화합물 및 이의 제조 및 사용 방법
WO2012103333A1 (en) 2011-01-26 2012-08-02 Zafgen Corporation Tetrazole compounds and methods of making and using same
CN103764652B (zh) 2011-05-06 2016-03-23 扎夫根股份有限公司 三环吡唑磺酰胺化合物及其制备和使用方法
MX343687B (es) 2011-05-06 2016-11-16 Zafgen Inc Compuestos sulfonamida tricíclica y métodos para su fabricación y uso.
WO2012154676A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Partially saturated tricyclic compounds and methods of making and using same
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
CA2861381A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
MX2014008706A (es) 2012-01-18 2015-03-05 Zafgen Inc Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
CA2866078C (en) 2012-03-01 2018-01-02 Allergan, Inc. Benzofuran-2-sulfonamide derivatives as chemokine receptor modulators
CA2890342A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds and methods of making and using same
EA028367B1 (ru) 2012-11-05 2017-11-30 Зафджен, Инк. Способы лечения заболеваний печени
CN104918928A (zh) 2012-11-05 2015-09-16 扎夫根股份有限公司 三环化合物及其制备方法和用途
JP6361168B2 (ja) * 2013-06-17 2018-07-25 Jsr株式会社 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物
CN103524386B (zh) * 2013-10-24 2016-05-18 江苏鼎龙科技有限公司 2-氨基-4-甲磺酰胺甲基苯甲酸甲酯的制备方法
US10709714B2 (en) 2013-11-22 2020-07-14 Clifton Life Sciences LLC Gastrin antagonists for treatment and prevention of osteoporosis
KR20170016754A (ko) * 2015-08-04 2017-02-14 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN106565509A (zh) * 2016-11-03 2017-04-19 江苏鼎龙科技有限公司 2‑氨基‑4‑甲氨基苯甲酸甲酯盐酸盐的制备方法
KR101894091B1 (ko) 2018-01-23 2018-08-31 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN108218806B (zh) * 2018-04-02 2019-03-01 上海馨远医药科技有限公司 一种n-叔丁氧羰基吗啉-3-羧酸的制备方法
CN111285806B (zh) * 2018-12-06 2022-04-15 中国医学科学院药物研究所 吡唑类化合物及其制备方法、用途和药物组合物
CN116675684B (zh) * 2023-08-02 2023-11-07 上海翰森生物医药科技有限公司 含炔基稠环类衍生物拮抗剂、其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200420D0 (en) * 1992-01-09 1992-02-26 James Black Foundation The Lim Amino acid derivatives
CA2167154A1 (en) 1993-08-10 1995-02-16 Sarkis Barret Kalindjian Gastrin and cck receptor ligands
WO1998025911A1 (fr) 1996-12-10 1998-06-18 Zeria Pharmaceutical Co., Ltd. Derives de 1,5-benzodiazepine
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE10134721A1 (de) * 2001-07-17 2003-02-06 Bayer Ag Tetrahydrochinoxaline
ITTO20020674A1 (it) 2002-07-26 2004-01-26 Rotta Research Lab Derivati antranilici ad attivita' anticolecistochininica (anti-cck-1), procedimento per la loro preparazione e loro uso farmaceutico
US6943170B2 (en) * 2002-11-14 2005-09-13 Bristol-Myers Squibb Company N-cycloalkylglycines as HIV protease inhibitors
DK1651621T3 (da) * 2003-08-08 2008-11-10 Janssen Pharmaceutica Nv 2-(Quinoxalin-5-ylsulfonylamino)benzamidforbindelser som CCK2-modulatorer
CA2581426A1 (en) * 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Sulfonamide compounds

Also Published As

Publication number Publication date
ATE403650T1 (de) 2008-08-15
AU2004265312B2 (en) 2010-05-20
EP1651622B1 (en) 2007-02-07
EA200600203A1 (ru) 2006-08-25
CA2534885A1 (en) 2005-02-24
JP4818110B2 (ja) 2011-11-16
SG131114A1 (en) 2007-04-26
BRPI0413449A (pt) 2006-10-17
DK1651622T3 (da) 2007-05-07
US7288651B2 (en) 2007-10-30
SI1651622T1 (sl) 2007-06-30
PT1651622E (pt) 2007-04-30
EP1651621A1 (en) 2006-05-03
MXPA06001482A (es) 2006-09-04
TW200521120A (en) 2005-07-01
CA2534887A1 (en) 2005-02-24
AR045930A1 (es) 2005-11-16
SI1651621T1 (sl) 2008-12-31
NZ545030A (en) 2009-08-28
ECSP066355A (es) 2006-08-30
CR8229A (es) 2008-09-10
HRP20080559T3 (en) 2009-01-31
US20050043310A1 (en) 2005-02-24
KR20060060007A (ko) 2006-06-02
US20050038032A1 (en) 2005-02-17
CN1863781A (zh) 2006-11-15
PL1651622T3 (pl) 2007-07-31
CN1863782A (zh) 2006-11-15
LT5410B (lt) 2007-03-26
US20080076918A1 (en) 2008-03-27
ZA200601946B (en) 2007-05-30
PT1651621E (pt) 2008-09-30
EP1651621B1 (en) 2008-08-06
ATE353322T1 (de) 2007-02-15
JP2007501841A (ja) 2007-02-01
LV13453B (en) 2007-02-20
IL173591A0 (en) 2006-07-05
WO2005016896A1 (en) 2005-02-24
ES2310294T3 (es) 2009-01-01
UA84025C2 (xx) 2008-09-10
IS8280A (is) 2006-01-31
PL1651621T3 (pl) 2009-01-30
DK1651621T3 (da) 2008-11-10
US7563895B2 (en) 2009-07-21
CY1106486T1 (el) 2012-01-25
LT2006017A (en) 2006-11-27
MXPA06001550A (es) 2006-09-04
AU2004265311A1 (en) 2005-02-24
US7304051B2 (en) 2007-12-04
AU2004265312A1 (en) 2005-02-24
DE602004004663D1 (de) 2007-03-22
DE602004015614D1 (de) 2008-09-18
ES2281834T3 (es) 2007-10-01
CA2534885C (en) 2013-06-04
EP1651622A1 (en) 2006-05-03
WO2005016897A1 (en) 2005-02-24
DE602004004663T2 (de) 2007-11-22
JP2007501842A (ja) 2007-02-01

Similar Documents

Publication Publication Date Title
NO20061122L (no) 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer
NO20072092L (no) Sulfonamidforbindelser
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
NO20081788L (no) Cyklopropylaminer som modulatorer av histamin-H3-reseptoren
NO20085029L (no) Substituerte pyridylamidforbindelser som modulatorer av histamin H3 reseptoren
ATE381539T1 (de) Dipeptidylpeptidase-hemmer zur behandlung von diabetes
ATE461217T1 (de) Glp-1-verbindungen
NO20044534L (no) Substituerte fenylacetamider og deres anvendelse som glukokinaseaktivatorer
NO20052512L (no) Purinforbindelser og anvendelse deav som kannabinoiode reseptorligander
EA200701467A1 (ru) Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
NO20060230L (no) Nye aminobenzofenonforbindelser
DK1478358T3 (da) Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
NO20052058D0 (no) Behandling av influensa.
DE50310516D1 (de) Fredericamycin-derivate
SE0301653D0 (sv) Novel compounds
NO20052580D0 (no) Blandinger for behandling av infeksjon av Flavivirida viruser
NO20055130L (no) Aminocykloheksyleter-forbindelser og deres anvendelse
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
NO20045554L (no) Fremgangsmate for behandling av diabetes
IL189286A0 (en) Novel cysteine protease inhibitors and their therapeutic applications
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
NO20055002L (no) Benzol[1,2,5]tiadiazolforbindelser
NO20052814D0 (no) Cytomodulerende peptider for behandling av interstitielle cystitt
ATE542796T1 (de) N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
NO20053562L (no) Nye aminobenzofenonforbindelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application